These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 6209007)
1. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies. Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007 [TBL] [Abstract][Full Text] [Related]
2. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology. Canellos GP; Skarin AT; Rosenthal DS; Moloney WC; Frei E Cancer Treat Rep; 1981; 65 Suppl 1():125-9. PubMed ID: 6173118 [TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
4. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819 [TBL] [Abstract][Full Text] [Related]
5. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis. Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406 [TBL] [Abstract][Full Text] [Related]
6. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Canellos GP; Skarin AT; Klatt MM; Rosenthal DS; Case DC; Pinkus GS; Jochelson MS; Yeap BY; Shipp MA Semin Hematol; 1987 Apr; 24(2 Suppl 1):2-7. PubMed ID: 2438777 [TBL] [Abstract][Full Text] [Related]
7. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). Skarin AT; Canellos GP; Rosenthal DS; Case DC; MacIntyre JM; Pinkus GS; Moloney WC; Frei E J Clin Oncol; 1983 Feb; 1(2):91-8. PubMed ID: 6199472 [TBL] [Abstract][Full Text] [Related]
8. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time. Levine AM; Tulpule A; Espina B; Boswell W; Buckley J; Rasheed S; Stain S; Parker J; Nathwani B; Gill PS Cancer; 1996 Aug; 78(3):517-26. PubMed ID: 8697399 [TBL] [Abstract][Full Text] [Related]
9. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas. Guglielmi C; Gherlinzoni F; Amadori S; Mazza P; Mantovani L; Lauria F; Martelli M; Zinzani PL; Greco V; Poletti G Haematologica; 1989; 74(6):563-9. PubMed ID: 2483401 [TBL] [Abstract][Full Text] [Related]